Allen & Overy advises GSK on the sale of Lucozade and Ribena to Suntory
Allen & Overy has advised GlaxoSmithKline (GSK) on the sale of its nutritional drinks brands Lucozade and Ribena to Suntory Beverage and Food Ltd (Suntory), the Japanese consumer goods company, for £1.35bn.
It is expected that the transaction will be completed by the end of the year, subject to regulatory approvals.
Under the agreement, Suntory will acquire global rights to the brands with the exception of Nigeria, where GSK Nigeria will continue to manufacture and distribute Lucozade and Ribena under licence from Suntory.
In addition, Suntory will acquire GSK’s Coleford manufacturing site, which is located in the Forest of Dean in the UK. The vast majority of existing employees at the site will transfer to Suntory under the provisions of English employment law.
The Allen & Overy team was led by corporate partners Ed Barnett and Andrew Ballheimer, with assistance from Matthew Appleton and Nigel Parker.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from The Lawyer
Analysis from The Lawyer
Which firms are cutting it in this era of slimline rosters, and who are the GC new brooms making clean sweeps? The Lawyer can reveal all
At the time of its launch Accutrainee was described as a revolutionary change to the training model. Has it proved to be so? Not really.